NASDAQ:OMGA Omega Therapeutics (OMGA) Stock Price, News & Analysis $1.36 +0.03 (+2.26%) (As of 02:49 PM ET) Add Compare Share Share Today's Range$1.31▼$1.3850-Day Range$1.22▼$2.0952-Week Range$1.22▼$6.30Volume130,754 shsAverage Volume1.01 million shsMarket Capitalization$75.01 millionP/E RatioN/ADividend YieldN/APrice Target$10.20 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Get Omega Therapeutics alerts: Email Address Omega Therapeutics MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside650.0% Upside$10.20 Price TargetShort InterestBearish27.24% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment1.47Based on 2 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($1.23) to ($1.06) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.46 out of 5 starsMedical Sector492nd out of 927 stocksBiological Products, Except Diagnostic Industry82nd out of 154 stocks 3.5 Analyst's Opinion Consensus RatingOmega Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 5 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageOmega Therapeutics has only been the subject of 4 research reports in the past 90 days.Read more about Omega Therapeutics' stock forecast and price target. Previous Next 1.0 Short Interest Percentage of Shares Shorted27.24% of the float of Omega Therapeutics has been sold short.Short Interest Ratio / Days to CoverOmega Therapeutics has a short interest ratio ("days to cover") of 15.4, which indicates bearish sentiment.Change versus previous monthShort interest in Omega Therapeutics has recently decreased by 0.71%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldOmega Therapeutics does not currently pay a dividend.Dividend GrowthOmega Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for OMGA. Previous Next 3.0 News and Social Media Coverage News SentimentOmega Therapeutics has a news sentiment score of 1.47. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.68 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Omega Therapeutics this week, compared to 1 article on an average week.Search InterestOnly 1 people have searched for OMGA on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days.MarketBeat FollowsOnly 2 people have added Omega Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -33% compared to the previous 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Omega Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders57.00% of the stock of Omega Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions97.47% of the stock of Omega Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Omega Therapeutics' insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Omega Therapeutics are expected to grow in the coming year, from ($1.23) to ($1.06) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Omega Therapeutics is -0.81, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Omega Therapeutics is -0.81, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioOmega Therapeutics has a P/B Ratio of 1.30. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Omega Therapeutics' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad InvestorPlace44-year Wall Street Vet: “Permanent devastation is coming to America”After 44 years on Wall Street, I've seen it all... Black Monday, the Great Recession, the Covid crash. But now a looming disaster is threatening America. And it's unlike anything we've ever experienced before.The information in this video is crucially valuable. About Omega Therapeutics Stock (NASDAQ:OMGA)Omega Therapeutics, Inc. operates as a clinical-stage biotechnology company. The company's OMEGA platform enables control of fundamental epigenetic processes to correct the root cause of disease by restoring aberrant gene expression to a range without altering native nucleic acid sequences. It also develops OTX-2002 for hepatocellular carcinoma; OTX-2101 for non-small cell lung cancer; omega epigenomic controllers (OEC) for inflammatory lung diseases, such as neutrophilic asthma, acute respiratory distress syndrome, dermatological, oncology, and rheumatological indications; OEC candidates for idiopathic pulmonary fibrosis; liver regeneration medicines; and OEC candidates for patients with diabetes and other conditions to treat corneal epithelial injury. In addition, the company develops OEC candidates for the treatment of alopecia, a disorder characterized by patches of non-scarring hair loss affecting the scalp and body. Omega Therapeutics, Inc. was incorporated in 2016 and is headquartered in Cambridge, Massachusetts.Read More OMGA Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart OMGA Stock News HeadlinesAugust 14, 2024 | globenewswire.comOmega Therapeutics Announces Jennifer Nelson, Ph.D., as Senior Vice President of ResearchAugust 8, 2024 | benzinga.comOmega Therapeutics (NASDAQ:OMGA) Stock Quotes, Forecast and News SummarySeptember 16, 2024 | InvestorPlace (Ad)44-year Wall Street Vet: “Permanent devastation is coming to America”After 44 years on Wall Street, I've seen it all... Black Monday, the Great Recession, the Covid crash. But now a looming disaster is threatening America. And it's unlike anything we've ever experienced before.August 6, 2024 | globenewswire.comOmega Therapeutics Reports Second Quarter 2024 Financial Results and Highlights Recent Company ProgressJune 24, 2024 | globenewswire.comOmega Therapeutics Announces Election of Richard N. Kender to Board of DirectorsMay 30, 2024 | globenewswire.comOmega Therapeutics To Participate In Two Upcoming Investor ConferencesMay 29, 2024 | globenewswire.comOmega Therapeutics Appoints Kaan Certel, Ph.D., as Chief Business OfficerMay 13, 2024 | markets.businessinsider.comBuy Rating Reaffirmed for Omega Therapeutics on Strong Clinical and Financial PerformanceSeptember 16, 2024 | InvestorPlace (Ad)44-year Wall Street Vet: “Permanent devastation is coming to America”After 44 years on Wall Street, I've seen it all... Black Monday, the Great Recession, the Covid crash. But now a looming disaster is threatening America. And it's unlike anything we've ever experienced before.May 8, 2024 | globenewswire.comOmega Therapeutics Presents New Preclinical Data at ASGCT 2024 Demonstrating Tunable and Durable Upregulation of Gene Expression with Epigenomic ControllersMay 7, 2024 | markets.businessinsider.com4 Analysts Have This To Say About Omega TherapeuticsMay 7, 2024 | finance.yahoo.comOmega Therapeutics First Quarter 2024 Earnings: Revenues Beat Expectations, EPS In LineMay 7, 2024 | markets.businessinsider.comBuy Rating Affirmed for Omega Therapeutics Amid Strong Financials and Promising OTX-2002 Clinical TrialsMay 6, 2024 | markets.businessinsider.comOmega Therapeutics Reports First Quarter 2024 Financial Results and Highlights Recent Company ProgressMay 6, 2024 | investorplace.comOMGA Stock Earnings: Omega Therapeutics Misses EPS, Beats Revenue for Q1 2024May 6, 2024 | globenewswire.comOmega Therapeutics Reports First Quarter 2024 Financial Results and Highlights Recent Company ProgressApril 23, 2024 | globenewswire.comOmega Therapeutics to Present New Preclinical Data on Epigenomic Upregulation at the American Society of Gene and Cell Therapy 27th Annual MeetingApril 9, 2024 | globenewswire.comOmega Therapeutics Presents New Preclinical Data at AACR 2024 Supporting the Potential of Precision Epigenomic ControlSee More Headlines Receive OMGA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Omega Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings8/06/2024Today9/16/2024Next Earnings (Estimated)11/14/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:OMGA CUSIPN/A CIK1850838 Webwww.omegatherapeutics.com Phone617-949-4360FaxN/AEmployees120Year FoundedN/APrice Target and Rating Average Stock Price Target$10.20 High Stock Price Target$12.00 Low Stock Price Target$6.00 Potential Upside/Downside+650.0%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage5 Analysts Profitability EPS (Most Recent Fiscal Year)($1.67) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-97,430,000.00 Net Margins-1,249.54% Pretax Margin-1,249.54% Return on Equity-156.48% Return on Assets-40.77% Debt Debt-to-Equity Ratio0.49 Current Ratio2.19 Quick Ratio2.19 Sales & Book Value Annual Sales$6.31 million Price / Sales11.88 Cash FlowN/A Price / Cash FlowN/A Book Value$1.05 per share Price / Book1.30Miscellaneous Outstanding Shares55,155,000Free Float23,717,000Market Cap$75.01 million OptionableOptionable Beta1.86 7 Energy Stocks to Buy and Hold ForeverDo you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.Get This Free Report Key ExecutivesMr. Mahesh Karande (Age 50)President, CEO & Board Director Comp: $910.39kMr. Joshua Reed M.B.A. (Age 51)Chief Financial Officer Comp: $659.39kDr. Yan Moore M.D. (Age 57)Chief Medical Officer Comp: $738.34kDr. Thomas McCauley Ph.D. (Age 55)Chief Scientific Officer Comp: $588.5kMs. Ling Zeng Esq. (Age 55)J.D., Chief Legal & Administrative Officer and Secretary Comp: $519.36kMr. Anthony MullinChief People OfficerMs. Barbara Y. Chan (Age 60)Senior Vice President of Finance Mr. Charles O'Donnell Ph.D.VP and Head of Computational Genomics & Data SciencesMore ExecutivesKey CompetitorsChimerixNASDAQ:CMRXKaryopharm TherapeuticsNASDAQ:KPTIInventivaNASDAQ:IVARenalytixNASDAQ:RNLXSangamo TherapeuticsNASDAQ:SGMOView All CompetitorsInstitutional OwnershipPoint72 Asset Management L.P.Sold 13,380 shares on 8/19/2024Ownership: 0.210%Squarepoint Ops LLCBought 222,395 shares on 8/14/2024Ownership: 0.403%Cubist Systematic Strategies LLCBought 13,873 shares on 8/14/2024Ownership: 0.057%XTX Topco LtdBought 83,939 shares on 8/12/2024Ownership: 0.152%Renaissance Technologies LLCBought 128,400 shares on 8/9/2024Ownership: 0.233%View All Institutional Transactions OMGA Stock Analysis - Frequently Asked Questions How have OMGA shares performed this year? Omega Therapeutics' stock was trading at $3.01 at the beginning of 2024. Since then, OMGA stock has decreased by 54.8% and is now trading at $1.36. View the best growth stocks for 2024 here. How were Omega Therapeutics' earnings last quarter? Omega Therapeutics, Inc. (NASDAQ:OMGA) announced its quarterly earnings results on Tuesday, August, 6th. The company reported ($0.30) EPS for the quarter, beating the consensus estimate of ($0.36) by $0.06. The company earned $2.13 million during the quarter, compared to analyst estimates of $1.25 million. Omega Therapeutics had a negative trailing twelve-month return on equity of 156.48% and a negative net margin of 1,249.54%. When did Omega Therapeutics IPO? Omega Therapeutics (OMGA) raised $126 million in an IPO on Friday, July 30th 2021. The company issued 7,400,000 shares at $16.00-$18.00 per share. Who are Omega Therapeutics' major shareholders? Omega Therapeutics' top institutional investors include Squarepoint Ops LLC (0.40%), Renaissance Technologies LLC (0.23%), Point72 Asset Management L.P. (0.21%) and XTX Topco Ltd (0.15%). Insiders that own company stock include Flagship Pioneering Inc and Richard A Young. View institutional ownership trends. How do I buy shares of Omega Therapeutics? Shares of OMGA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:OMGA) was last updated on 9/16/2024 by MarketBeat.com Staff From Our PartnersMore Than 30 Federal Agencies Buy From This Cybersecurity TechIn January of 2022 Ukraine was hit by an especially nasty piece of malware, named WhisperGate. By then Ukra...Capital Trends | Sponsored44-year Wall Street Vet: “Permanent devastation is coming to America”After 44 years on Wall Street, I've seen it all... Black Monday, the Great Recession, the Covid crash. B...InvestorPlace | SponsoredBREAKING NEWS: AI Tech Now Used to Stop School ShootersTwo seconds. That's all it takes for Knightscope's Automated Gunshot Detection to notify authorities and map a...Market JAR | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredNvidia needs these 3 companies on a new $1 trillion SuperprojectNvidia is pivoting to a new $1 trillion Superproject that could revolutionize the AI industry… again. And i...Weiss Ratings | SponsoredUnlock the Secret to Easy Wins with Iron CondorsDiscover the power of Iron Condor trades – a low-risk, high-reward strategy that allows you to profit consiste...Netpicks | SponsoredWhy Institutions Are Bullish on BitcoinThe recent dip in the crypto market might be stressful… But it also presents a tremendous opportunity for s...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Omega Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Omega Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free OMGA Stock Alerts